title: Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement.
abstract: The influence of hypothyroidism on haemostasis is an active research area. Not only bleeding tendency but also hypercoagulable states have been reported in hypothyroid patients. Decreased and increased fibrinolytic activity in hypothyroid patients has been shown in several studies. Thrombin activatable fibrinolysis inhibitor (TAFI) is an inhibitor of fibrinolysis, which has been recently isolated from human plasma. The aim of our study was to determine plasma TAFI antigen levels in overt and subclinical hypothyroidism, and to investigate the effect of levothyroxine treatment on TAFI levels. The study was performed in age- and sex-matched 30 overt hypothyroid, 30 subclinical hypothyroid patients, and 30 healthy controls. Blood samples were obtained from patients with overt and subclinical hypothyroidism before levothyroxine replacement, and one month after achieving a euthyroid state with levothyroxine. TAFI antigen levels were measured using Enzyme-Linked ImmunoSorbent Assay kits (Affinity Biologicals; Ontario, Canada). In baseline evaluation both the overt and subclinical hypothyroid groups had higher TAFI antigen levels than control group (p<0.05). High levels of TAFI antigen were correlated with the degree of thyroid failure. After achieving euthyroid state with levothyroxine replacement, TAFI antigen levels decreased significantly in patients with overt and subclinical hypothyroidism (p<0.05). Our data suggest that there are elevated plasma levels of TAFI antigen both in overt and subclinical hypothyroidism, which may be associated with hypofibrinolysis and elevated risk of thrombosis. Normalization of thyroid state by levothyroxine replacement seems to be effective in lowering of TAFI antigen levels in hypothyroidism.
authors.affiliation: Dokuz Eylul University Medical School, Department of Internal Medicine, Division of Endocrinology and Metabolism, Izmir, Turkey.
authors.forename: Baris
authors.initials: B
authors.lastname: Akinci
authors.forename: Abdurrahman
authors.initials: A
authors.lastname: Comlekci
authors.forename: Mehmet
authors.initials: M
authors.lastname: Ali Ozcan
authors.forename: Tevfik
authors.initials: T
authors.lastname: Demir
authors.forename: Serkan
authors.initials: S
authors.lastname: Yener
authors.forename: Fatih
authors.initials: F
authors.lastname: Demirkan
authors.forename: Faize
authors.initials: F
authors.lastname: Yuksel
authors.forename: Sena
authors.initials: S
authors.lastname: Yesil
mesh_terms: D000328:Adult; D000368:Aged; D000941:Antigens / Q000097:blood; D025901:Carboxypeptidase B2 / Q000097:blood* / Q000276:immunology; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D007037:Hypothyroidism / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012107:Research Design; D013974:Thyroxine / Q000627:therapeutic use*
chemical_list: D000941:Antigens; D025901:Carboxypeptidase B2; D013974:Thyroxine